Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2-positive metastatic colorectal cancer.

PubMed 2026 Open access

Read full text
Authors: Claire Watkins, Cyndy Simon, Peter Martin, Regina M. Leadley, Gabrielle Redhead, Edward E. Neuberger, Karen Bartley
DOI: 10.57264/cer-2025-0017
Cited by: 0

Abstract

These data support that tucatinib in combination with trastuzumab is an effective therapy option in patients with previously treated mCRC.

Fields of Study & Subjects

Colorectal Cancer Treatments and Studies HER2/EGFR in Cancer Research Gastric Cancer Management and Outcomes

Publication details

Journal / source
PubMed
Volume
15
Issue
2
Pages
e250017–e250017
Publication date
1 February 2026
Language
EN